<li>amobarbital<p>amobarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>armodafinil<p>armodafinil will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>blessed thistle<p>blessed thistle decreases effects of lansoprazole by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>bortezomib<p>bortezomib will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>bosentan<p>bosentan will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>butalbital<p>butalbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>cyanocobalamin<p>lansoprazole decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>darifenacin<p>darifenacin decreases effects of lansoprazole by Other (see comment). Minor/Significance Unknown. 
Comment: Effectiveness of proton pump inhibitors may be decreased theoretically if administered with other antisecretory agents.</p></li><li>darunavir<p>darunavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dasatinib<p>dasatinib increases levels of lansoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>delavirdine<p>delavirdine increases levels of lansoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>devil's claw<p>devil's claw decreases effects of lansoprazole by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df, lansoprazole. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Based on drug interaction studies conducted with the components of Stribild, no clinically significant drug interactions have been either observed or are expected when coadministered with PPIs.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>etravirine<p>etravirine will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>ferric carboxymaltose<p>lansoprazole will decrease the level or effect of ferric carboxymaltose by  increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.<span><br><br></span>fluconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>indinavir<p>indinavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>levothyroxine<p>lansoprazole decreases levels of levothyroxine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liothyronine<p>lansoprazole decreases levels of liothyronine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liotrix<p>lansoprazole decreases levels of liotrix by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>lisdexamfetamine<p>lansoprazole, lisdexamfetamine. Other (see comment). Minor/Significance Unknown. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>methamphetamine<p>lansoprazole decreases levels of methamphetamine by Other (see comment). Minor/Significance Unknown. 
Comment: Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone; monitor patients for changes in clinical effect and adjust therapy based on clinical response.</p></li><li>methylprednisolone<p>methylprednisolone will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>modafinil<p>modafinil will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Net effect on pantoprazole actions unknown due to opposing effects of CYP450 enzymes; monitor 	<span><br><br></span>modafinil will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Net effect on pantoprazole actions unknown due to opposing effects of CYP450 enzymes; monitor 	</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxcarbazepine<p>oxcarbazepine will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>phytoestrogens<p>lansoprazole decreases levels of phytoestrogens by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>primidone<p>primidone will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>rifampin<p>rifampin will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sucralfate<p>sucralfate decreases levels of lansoprazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 30 minutes.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>theophylline<p>lansoprazole increases levels of theophylline by decreasing metabolism. Minor/Significance Unknown.<span><br><br></span>lansoprazole increases toxicity of theophylline by Other (see comment). Minor/Significance Unknown. 
Comment: Prolonged use of proton pump inhibitors can cause hypochlorhydria, which in turn causes peristalsis in small intestine to increase and peristalsis in the proximal colon to decrease; monitor for toxicity.</p></li><li>thyroid desiccated<p>lansoprazole decreases levels of thyroid desiccated by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.<span><br><br></span>voriconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li>